Biotica inks $195M licensing deal with Wyeth

UK-based Biotica Technology has signed a licensing deal with Wyeth for up to $195 million in up-front payments and milestones in addition to royalties from any drugs developed as part of the collaboration. Wyeth gains rights to Biotica's advanced drug candidates, a portfolio of additional rapamycin analogs, and the technology to discover new compounds.

"We look forward to working with Wyeth to maximize the commercial potential of our novel rapamycin analogs and discovery platform. Wyeth is our ideal partner for this collaboration because of its leadership in the discovery, development and commercialization of this class of molecules." says Dr. Mark Bodmer, CEO of Biotica. In a statement, Wyeth said that Biotica's rapamycin analogs are a good fit for the company's rapamycin franchise.

- see the release on Biotica's licensing deal

Suggested Articles

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.